RecruitingPhase 2Phase 3NCT06702241

Newborn Jaundice - An Investigation of Different Approaches to Light Therapy

Neonatal Hyperbilirubinemia - Phototherapeutic Treatment Strategies


Sponsor

Regionshospital Nordjylland

Enrollment

116 participants

Start Date

Jan 14, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Background Neonatal jaundice affects about 60% of full-term newborns in their first week. If untreated, it can lead to permanent brain damage. In Denmark, 2-5% of newborns require phototherapy, the standard treatment. The maximum beneficial irradiance limit for phototherapy remains unclear. Furthermore, studies suggest that cycled phototherapy is as effective as continuous treatment. This study aims to investigate the efficacy of elevating the irradiance of intensive phototherapy treatment regimens. This is to evaluate the dose-response relationship. Furthermore, the study aims to compare intermittent phototherapy to continuous phototherapy. Methods: In a clinical randomized multicenter trial 116 newborns with non-hemolytic hyperbilirubinemia, gestational age \>33+0, weight \>1800g and no other significant neonatal diagnose will be randomized. All infants will receive 12 hours double therapy with a biliblanket and overhead light providing an intensity of either 40-, 55- or 70 µW/cm2/nm. Three groups will be treated with continuous phototherapy while a fourth group will receive intermittent phototherapy of 1,5 hours cycled intervals with an intensity of 70 µW/cm2/nm. Parental experiences during treatment will be examined through a survey post treatment. The study has been approved by the Regional Research Ethics Committee. Perspectives: Understanding the dose-response relationship of phototherapy will give an insight in the most effective way of treating neonatal jaundice. Intermittent therapy, if proven non-inferior, could facilitate more intimacy in the parent-infant relationship as well as benefits in initiating breastfeeding


Eligibility

Min Age: 1 DayMax Age: 14 Days

Inclusion Criteria3

  • Hyperbilirubinemia with a total serum bilirubin level above the limit of necessary treatment according to the Danish Pediatric Society's guidelines
  • Birth weight >1800g
  • Gestational age >33+0

Exclusion Criteria2

  • Hyperbilirubinemia within the first 24 hours of life
  • Rapidly increasing serum levels of bilirubnemia indicating pathology or hemolysis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERContinuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light

The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.

OTHERContinuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light

The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght

OTHERContinuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light

The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght

OTHERCycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light

The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght


Locations(2)

Aalborg University Hospital, The Neonatal Department

Aalborg, Denmark

The North Denmark Regional Hospital, The Pediatric Department

Hjørring, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06702241


Related Trials